Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: Evidence for tone-dependent normalization of striatal dopaminergic activity

Synapse

Volumn 28, Issue 4, 1998, Pages 280-287

  Tedroff, J ^a,c   Torstenson, R ^a,c   Hartvig, P ^a,c   Sonesson, C ^b   Waters, N ^b   Carlsson, A ^b   Neu, H ^a,c   Fasth, K J ^a,c   Langstrom B ^a,c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

( ) OSU6162; Dopamine; Monkey; PET, L 11C DOPA

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; 3 METHYLSULFONYLPHENYL 1 PROPYLPIPERIDINE; CARBON 11; DOPAMINE 2 RECEPTOR; LEVODOPA; PIPERIDINE DERIVATIVE; SAPROPTERIN; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG TRANSPORT; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MACACA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; BIOPTERIN; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; FEMALE; LEVODOPA; MACACA MULATTA; PIPERIDINES; REFERENCE VALUES; TOMOGRAPHY, EMISSION-COMPUTED; TYROSINE;

EID: 0031913840     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199804)28:4<280::AID-SYN3>3.0.CO;2-5     Document Type: Article

References (41)

1. Ahlenius, S., and Salmi, P. (1994) Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur. J. Pharmacol., 260:177-1819.
2. Andersson, J.L.R. (1995) A rapid and accurate method to realign PET scans utilizing image edge information. J. Nucl. Med., 36:657-669.
3. Bergström, M., Hartvig, P., Nava, C., de Paolis, C., and Långström, B. (1995) Effects of cabergoline on striatal dopamine receptor binding and dopamine synthesis - in vivo study in monkey with positron emission tomography. Abstract. European Neuroscience Meeting, Amsterdam, Netherlands, p. 24.
4. 11C-labelled L-tyrosine and L-DOPA. Acta Chem. Scand., 44:183-188.
5. Carlsson, A. (1975a) Dopaminergic Autoreceptors. In: Chemical Tools in Catecholamine Research. O. Almgren, A. Carlsson, and J. Engel, eds. North-Holland Publishing Company, pp. 219-225.
6. Carlsson, A. (1975b) Receptor-mediated control of dopamine metabolism. In: Pre- and Postsynaptic Receptors. E. Usdin and W.E. Bunney, Jr., eds. Marcel Dekker Inc., pp. 49-65.
7. Carlsson, M., and Carlsson, A. (1990) Schizophrenia: A subcortical neurotransmitter inbalance syndrome? Schizophr. Bull., 16:425-432.
8. Carson, R.E., Huang, S.-C., and Green, M.V. (1986) Weighted integration method for local cerebral blood flow measurements with positron emission tomography. J. Cereb. Blood Flow Metab., 6:245-258.
9. Chiodo, L.A. (1992) Dopamine autoreceptor signal transduction in the DA vell body: A "current view." Neurochem. Int., 20:S81-S84.
10. Clark, D., Hjorth, S., and Carlsson, A. (1985) Dopamine receptor agonists: Mechanism underlying autoreceptor selectivity. I. Review of the evidence. J. Neural Transm., 62:1-52.
11. Cross, A.J., Crow, T.J., Ferier, I.N., Johnson, E.C., McCreadie, R.M., Owen, F., Owen, D.G.C., and Poulter, M. (1983) Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder. J. Neural. Transm. Suppl., 18:S265-S272.
12. Di Chiara, G., Porceddu, M.L., Vargiu, L., Argiolas, A., and Gessa, G.L. (1976) Evidence for dopamine receptors mediating sedation in the mouse brain. Nature, 264:564-567.
13. Ekesbo, A., Andrén, P., Gunne, L.M., and Tedroff, J. (1997) (-)-OSU6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Neuroreport, 8:2567-2570.
14. 2 autoreceptor ligands: Modeling of dopamine synthesis and release in vivo by means of partial least squares regression. J. Med. Chem., 38:3121-3131.
15. 11C] -L-DOPA following COMT inhibition. A study in vivo using PET. J. Neural Transm. Gen. Sect. 87:15-22.
16. Holte, S., Eriksson, L., and Dahlbom, M. (1989) A preliminary evaluation of Scanditronix PC 2048-15B scanner. Eur. J. Nucl. Med., 15:719-721.
17. Kenakin, T. (1996) Receptor conformational induction versus selection: All part of the same energy landscape. Trends Pharmacol. Sci., 17:190-191.
18. Kops, R.E., Herzog, H., Schmid, A., Holte, S., and Feinendegen, L. (1990) Performance characteristics of an eight ring whole body PET scanner. J. Comput. Assist. Tomogr., 14:437-445.
19. Metman, L.V., Sethy, V.H., Roberts, J.R., Bravi, D., Hoff, J.I., Mouradian, M.M., and Chase, TN. (1994) Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease. Mov. Disord., 9:577-581.
20. Milligan, G., Bond, R.A., and Lee, M. (1995) Inverse agonism: Pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci., 16:10-13.
21. 11C-methyl]-( -)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography. Nucl. Med. Biol. 24:507-511.
22. Pirtosek, Z., Merello, M., Carlsson, A., and Stern, G. (1993) Preclamol and Parkinsonian fluctuations. Clin. Neuropharmacol., 16:550-554.
23. Roth, R.H. (1979) Dopamine autoreceptors: Pharmacology, function and comparison with postsynaptic dopamine receptors. Commun. Psychopharmacol., 3:429-445.
24. Seeman, P., and Niznik, H.B. (1990) Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J., 4:2737-2744.
25. Sonesson, C. (1995) Arylpiperidine and Arylpyrrolidine Derivatives With Potential Antipsychotic Efficacy. Synthesis and Quantitative Structure Activity relationships. Thesis, University of Uppsala, Sweden, ISBN 91-554-3453-3, 53-54.
26. Sonesson, C., and Lindborg, J. (1994) An efficient synthesis of the novel dopamine autoreceptor antagonist S-(-)-6162, via palladium catalyzed cross-coupling reaction. Tetrahedron. Lett., 35:9063-9066.
27. Sonesson, C., Lin, C.-H., Hansson, L., Waters, N., Svensson, K., Carlsson, A., Smith, M.-W., and Wikström, H. (1994) Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: Synthesis and structure-activity relationships. J. Med. Chem., 37:2735-2753.
28. Strömberg, U. (1970) DOPA Effects on motility in mice: Potentiation by MK485 and dexchlorpheniramine. Psychopharmacologica (Berl.), 18:58-67.
29. Strömbom, U. (1976) Catecholamine receptor agonists. Naunyn Schmiedeberg's Arch. Pharmacol., 292:167-176.
30. Tamminga, C.A., Cascella, N.G., Lahti, R.A., Lindberg, M., and Carlsson, A. (1992) Pharmacological properties of (-)-3PPP (preclamol) in man. J. Neural Transm. Gen. Sect., 88:165-175.
31. Tani, Y., Ishihara, T., Kanai, T., Ohno, T., Andersson, J., Lilja, A., Antoni, G., Fasth, K.J., Bjurling, P., Westerberg, G., Hartvig, P., Onoe, H., Watanabe, Y., and Långström, B. (1996) Effects of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin on the dopaminergic and cholinergic receptor as evaluated by positron emission tomography in the rhesus monkey. J. Neural. Transm. Gen. Sect., 102:189-208.
32. Tedroff, J., Hartvig, P., Bjurling, P., Andersson, Y., Antoni, G., and Långström, B. (1991) Central action of benserazide after COMT inhibition demonstrated in vivo by PET. J. Neural Transm. Gen. Sect., 85:11-17.
33. 11C]-L-3,4-dihydroxyphenyl alanine (DOPA) in the primate by positron emission tomography. Acta Neurol. Scand., 85:166-173.
34. 11C]raclopride displacement and PET. Neurology, 46:1430-1436.
35. Tedroff, J., Torstenson, R., Hartvig, P., Lindner, K.J., Watanabe, Y., Bjurling, P., Westerberg, G., and Långström, B. (1997) L-DOPA modulates striatal dopaminergic function in vivo. Evidence from PET investigations in nonhuman primates. Synapse, 25:56-61.
36. Tissari, A.H., and Lillgals, M.S. (1993) Reduction of dopamine synthesis inhibition by dopamine autoreceptor activation in striatal synaptosomes with in vivo reserpine administration. J. Neurochem., 61:231-238.
37. Torstenson, R., Hartvig, P., Långström, B., Westerberg, G., and Tedroff, J. (1997) Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann. Neurol., 41:334-340.
38. 11C]DOPA disposition in the monkey brain. Brain Res., 713:92-98.
39. 2 receptor. Trends Pharmacol. Sci., 10:74-77.
40. Waters, N., Svensson, K., Haadsma-Svensson, S.R., Smith, M.W., and Carlsson, A. (1993) The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity. J. Neural Transm. Gen. Sect, 94:11-19.
41. 3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour. J. Neural Transm. Gen. Sect., 98:39-55.